Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) was up 2.4% on Wednesday . The stock traded as high as $4.40 and last traded at $4.32. Approximately 471,895 shares traded hands during trading, a decline of 3% from the average daily volume of 486,688 shares. The stock had previously closed at $4.22.
Eliem Therapeutics Price Performance
The business has a 50-day simple moving average of $3.17 and a 200 day simple moving average of $2.35. The firm has a market cap of $128.53 million, a PE ratio of -8.15 and a beta of -0.39.
About Eliem Therapeutics
Eliem Therapeutics, Inc is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.
The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.
See Also
- Five stocks we like better than Eliem Therapeutics
- A month before the crash
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Your Bank Account Is No Longer Safe
- Bitcoin is down but your income is about to explode
- Trump Devises the Death of the IRS ☠️
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
